UBS Group’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

UBS Group’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,537	Closed	-$15.5K	–	11353
2022 Q4	$15.5K	Hold	1,537	–	–	﹤0.01%	7969
2022 Q3	$15K	Hold	1,537	–	–	﹤0.01%	7874
2022 Q2	$15K	Hold	1,537	–	–	﹤0.01%	7352
2022 Q1	$15K	Buy	1,537 +1,368	+809%	+$13.3K	﹤0.01%	7882
2021 Q4	$2K	Hold	169	–	–	﹤0.01%	9900
2021 Q3	$2K	Buy	+169	New	+$1.63K	﹤0.01%	9055

UBS Group's EBAC Position: Q1 2023 in Review

UBS Group sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 1,537 shares — an estimated $15.5K sold.

UBS Group first reported a position in EBAC in Q3 2021 and held it in 6 quarters. The position peaked at $15.5K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

UBS Group reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
UBS Group sold 1,537 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $15.5K.
UBS Group first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
UBS Group's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $15.5K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.